PINK1/Parkin Activators represent a promising therapeutic approach for Parkinson's disease and other neurodegenerative disorders characterized by mitochondrial dysfunction. This page provides comprehensive information about the PINK1/Parkin pathway, therapeutic strategies, and current research progress. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Mitochondrial Quality Control | [4]
| Target | PINK1/Parkin Mitophagy Pathway | [5]
| Diseases | Parkinson's Disease, Dementia with Lewy Bodies, Multiple System Atrophy | [6]
| Stage | Preclinical to Phase I | [7]
The PINK1/Parkin pathway is a critical mitochondrial quality control mechanism. Loss-of-function mutations in PRKN (Parkin) and PINK1 (PTEN-induced kinase 1) genes cause early-onset familial Parkinson's disease, highlighting the therapeutic potential of activating this pathway. [8]
| Compound | Mechanism | Development Stage |
|---|---|---|
| Rapamycin | mTOR inhibition, indirect mitophagy enhancement | Preclinical |
| Nicotinamide | NAD+ boost, SIRT1 activation | Preclinical |
| Urolithin A | Mitophagy induction via BET inhibition | Phase III (gut) |
| Rapamycin analogs | mTORC1 inhibition | Various stages |
PINK1/Parkin activators work synergistically with:
The study of Pink1 Parkin Activators has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. 2015. ↩︎
Narendra D, et al. Parkin is recruited selectively to impaired mitochondria and activates their autophagy. 2010. ↩︎
Matsuda N, et al. PINK1 stabilized by mitochondrial membrane potential regulates parkin E3 ligase activity. 2014. ↩︎
Kazlauskaite A, et al. Phosphorylation of parkin at Serine65 is essential for its activation. 2014. ↩︎
McWilliams TG, et al. Phosphorylation of ubiquitin as a marker of mitochondrial dysfunction. 2015. ↩︎
Ryan BJ, et al. PINK1 and parkin: mitochondrial quality control in neurodegeneration. 2018. ↩︎
Eiyama A, Okamoto K. PINK1/Parkin in neurodegeneration. 2015. ↩︎
Scarffe LA, et al. Parkin and PINK1: much more than mitophagy. 2014. ↩︎